Biovica International
2.615
SEK
-2.06 %
BIOVIC B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-2.06%
+19.68%
+0.58%
+3.36%
+1.36%
-0.57%
-92.11%
-75.23%
-76.48%
biovica.com/investor-relations
Biovica International is a pharmaceutical company that focuses its research on cancer treatments. The company is developing methods for measuring cell proliferation, where the test is taken via blood samples. The tests analyze the risk for the development of the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main area of focus is within treatment of breast cancer. The company was founded in 2008 and is headquartered in Uppsala.
Revenue
7.29M
EBIT %
-1,740.05 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
BIOVIC B
Daily low / high price
2.53 / 2.765
SEK
Market cap
255.71M SEK
Turnover
313.36K SEK
Volume
118K
Latest videos
Financial calendar
Interim report
12.12.2024
Interim report
13.03.2025
Annual report
19.06.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Anders Rylander Investment AB | 10.9 % | 17.0 % |
| Avanza Pension | 5.0 % | 4.4 % |
| Nordnet Pension Insurance | 3.7 % | 3.2 % |
| Mattias Sesemann | 3.5 % | 3.1 % |
| Mats Danielsson | 3.3 % | 2.9 % |
| Handelsbanken Life Insurance AB | 3.2 % | 2.8 % |
| Britta Ingeborg Rylander | 1.8 % | 3.4 % |
| Lars Holmqvist | 1.6 % | 1.4 % |
| Gunvald Berger | 1.4 % | 1.3 % |
| Göran Brorsson | 1.2 % | 1.1 % |
ShowingAll content types
New DiviTum® TKa data to be presented at SABCS that significantly broaden the addressable market
Biovica signs agreement with UK biotech company
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools